New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
08:36 EDTNBSNeoStem announces grant of two U.S. patents for CD34 cell program
NeoStem announced the expansion of intellectual property protection surrounding its CD34 Cell Program. That program is developing therapeutics to address ischemia, the process that occurs when the supply of oxygenated blood in the body is restricted. The recently granted U.S. patents relate to AMR-001, the company's most clinically advanced product candidate in its CD34 Cell Program, which is designed to treat damaged heart muscle following acute myocardial infarction. U.S. patents 8,637,005 and 8,709,403 are entitled "Compositions and Methods of Vascular Injury Repair" and serve to further expand the range of serum concentrations used to deliver CD34 cells from claims of previously granted patents. These patents bring the total number of granted and allowed patents for the Company's CD34 cell program to 16.
News For NBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
16:09 EDTNBSNeoStem provides 2015 outlook
In 2015, NeoStem's management expects significant additional achievements. The Company's milestones and goals for the year include: Randomization of the first patient for the Intus Phase 3 trial for NBS20 in the second quarter of 2015; Release of one-year data from PreSERVE AMI Phase 2 trial for NBS10 on March 15, 2015 at the Annual Scientific Sessions of the American College of Cardiology; Finalization of decision on next development steps for NBS10 based on PreSERVE primary analysis results in the second half of 2015; Initiation of a Phase 2 study for which NeoStem has received FDA agreement on the protocol to evaluate in adolescents the use of NBS03D, a Treg-based therapeutic being developed to treat type 1 diabetes, in late 2015 or 2016 depending on resource availability; Further exploration of means by which the Company can take advantage of new regulations in Japan that permit conditional approval for regenerative medicine products that show sufficient safety evidence and signals of efficacy; Continued growth of the Company's client services business; Advancement of initiatives to lower costs and improve efficiency of manufacturing in anticipation of production for NeoStem's own products and those of its clients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use